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Abstract: Spinal cord injury (SCI) is one of the most devastating traumas for an 
individual because the complete traumatic spinal cord injury leads to paraplegia or 
tetraplegia. The mechanical injuries directly cause axonal destruction in fiber tracts, 
destruction of the neurons and of the glial cells, and their destruction releases substances 
whose presence, quantity and dynamics can be lesional biomarkers. The reactions of 
partially injured cells simultaneously start and the occurring substances and their 
quantity may be reaction biomarkers. The lesional biomarkers appear immediately post-
injury and after several hours there are both lesional biomarkers and reaction 
biomarkers. The most important lesional biomarkers are the phosphorylated 
neurofilament subunits resulting from the axonal neurofilament destruction.  The heavy 
phosphorylated neurofilament subunit (pNF-H) is a predictive lesional biomarker 
because its values pattern can show the reducing or stopping of the secondary lesions 
and the favorable outcome. The complete SCI patients with a favorable development had 
a specific pattern of daily values of pNF-H: a sudden increase up to a maximum value 
then a progressive decrease to normal. The patients with unfavorable outcome or 
neurological stabilisation had two patterns: an increase to a plateau of pNF-H values or 
a progressive increase up to a peak followed by a progressive decrease to quasi-normal 
values. 
Key words: lesional biomarker, phosphorylated neurofilament subunit, reactional 
biomarker, spinal cord injury 
 
Introduction 
Spinal cord injury (SCI) is one of the most 
devastating traumas for an individual and 
their family because, depending on the level of 
injury, the complete traumatic spinal cord 
injury leads to paraplegia or tetraplegia. 
Immediate traumatic spinal cord injury is the 
primary mechanical injury caused through the 
direct injury of the neurons, axons and blood 
vessels (compression, laceration, shearing and 
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even transection of the spinal cord). After the 
injury event, the secondary injury mechanisms 
begin immediately and the secondary spinal 
cord lesions consist of hemorrhages, spinal 
cord edema, vasospasm and hypo-perfusion of 
the spinal cord and the damage of the spinal 
cord continues to progress for several days to 
weeks, and leads to the death of neurons and 
the interruption of the axonal tracts. 
Many traumatic spinal cord injuries can be 
initially incomplete and the secondary damage 
completes the lesion of the spinal cord. Spinal 
cord injuries are difficult to treat because of 
these secondary injuries. Current therapy is 
unable to act on the primary mechanically 
lesion, but the secondary injury extension of 
the spinal cord could be stopped or reduced by 
an early efficient therapy. 
In SCI the neurological examination brings 
the first very important information about the 
lesion and this directs imaging procedures to 
confirm the lesion. But because of the spinal 
shock, unstable condition of the patient, 
attendant injuries, alcohol or drugs etc., the 
clinical examination immediately following 
injury, even using the ASIA motor scores or 
other scales, cannot be considered reliable. 
These clinical examinations must be repeated, 
but they offer only static clinical states and no 
data about possible future development. 
Biomarkers are measurable features that 
can be used to confirm the presence or to 
predict the severity of the disorders. 
Biomarkers as biochemical indicators in SCI 
can allow detection of the secondary lesion, 
can monitor its progress and predict the 
severity of SCI and can also indicate the 
specific treatments required.  In SCI 
biomarkers detect the severity of injury within 
the first few hours and can direct the best 
patient care in a timely manner.  
In acute traumatic SCI, the mechanical 
injuries directly cause axonal destruction in 
fiber tracts, destruction of the neurons in gray 
matter and of the glial cells. Their destruction 
releases substances - cellular constituents, 
whose presence, quantity and dynamics can be 
lesional biomarkers. Detecting these protein 
changes, their quantity and dynamics may be 
biomarkers of response, or reaction 
biomarkers. 
Correlating the lesional biomarkers and 
the reaction biomarkers with the clinical 
outcome and with the imaging techniques will 
enable understanding the complexity of the 
biological response to spinal cord injury and 
the establishment of appropriate therapies  
The lesional biomarkers appear immediately 
post-injury and their dynamics show the 
extension of the spinal cord injury and after 
several hours there are both lesional 
biomarkers and reaction biomarkers, 
involving the secondary cellular response to 
injury. 
Biomarkers and the diagnostic value in SCI   
In recent years a number of protein 
biomarkers have been evaluated to detect 
neuronal injury and recently there have been 
studies about their potential diagnostic and 
predictive value for spinal cord injuries.  The 
concentration of specific proteins in blood or 
in the cerebrospinal fluid must be compared 
with the nervous tissue injury and these can be 
biomarkers for the pathologic processes in 
spinal cord injury.    
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There are numerous experimental studies 
and a smaller number of clinical studies for 
determining and validating biomarkers in 
spinal cord injury: c-Tau, myelin basic protein 
– MBP, neuron-specific enolase – NSE, glial 
fibrillar acidic protein – GFAP etc.   New 
potential biomarkers were reported: the 
neurofilaments, the major cytoskeletal 
components in axon fibers. The most 
important are neurofilament subunit proteins 
(NF) that coassemble forming the cytoskeletal 
of axon fibers and they consist of five subunits 
of neurofilaments, named on the basis of 
molecular weight: heavy or highest (NF- H, 
200 – 220 kDa), medium or middle (NF-M, 
145-160 kDa) and light or lowest (NF-L, 68-70 
kDa) subunits, also alpha-internexin subunit 
(NF66) discovered later than NF and the 
intermediate filament protein subunit 
peripherin. 
Ueno et al. (2011) presented a rat model of 
acute spinal cord injury and they showed that 
the high-molecular-weight neurofilament 
subunit levels in plasma could be a biomarker 
for evaluating the efficacy of therapies for SCI.  
Hayakawa et al. (2012) studied the 
concentration of the phosphorylated 
neurofilament subunit NF-H (pNF-H) in 
plasma in patients with acute cervical SCI and 
concluded pNF-H may be a prognostic 
biomarker for SCI.    The pNF-H 
concentration was measured by ELISA test in 
CSF in acute spinal cord injury patients and 
correlated the values of pNF-H with the 
clinical evolution. The phosphorylated form of 
the neurofilament subunit NF-H (pNF-H) is a 
biomarker in SCI in humans and its increased 
values are consistent with an unfavorable 
outcome. The neurofilament subunit NF-H 
(pNF-H) is a lesional biomarker, it appears 
after the mechanical injury by axonal 
destruction in the fibers tracts. By now these 
studies have identified some potential 
biomarkers, but these biomarkers have not 
been validated and they still cannot be used in 
the clinical setting, for diagnosis, prognosis 
and evaluating therapeutic interventions. 
Current status of biomarkers in traumatic 
spinal cord injury 
The research in traumatic spinal cord 
injury has been focused on the discovery of 
lesional biomarkers and lesser for reaction 
biomarkers.  Lesional biomarkers can be 
studied in patients with acute traumatic SCI 
immediately after injury; reaction biomarkers 
occur after a short period post injury and after 
several hours post injury these two types of 
biomarkers coexist, and it is difficult to 
differentiate them. The study of reaction 
biomarkers involves cells around the lesion, 
which is not possible in patients with SCI. 
Therefore research is conducted on nerve cell 
cultures and there are experimental animal 
models, but the translation into human 
medicine is difficult because there are 
important differences. The most important 
studies on lesional biomarkers concerns the 
neurofilament subunit proteins (NF).  
The phosphorylated neurofilament 
subunit NF-H (pNF-H) was measured in the 
cerebro-spinal fluid of patients with spinal 
cord injury and it was demonstrated the 
correlation between the pNF-H levels and the 
severity of the injury. The study included 
subjects with acute traumatic spinal cord 
injury who underwent surgery during the first 
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24 hours post injury (decompression, 
stabilization): patients with complete spinal 
cord injury (SCI) and patients with incomplete 
SCI. The level of CSF pNF-H was ten to a 
hundred times higher in complete SCI than 
the level of CSF pNF-H in cases with 
incomplete SCI, where the level of this 
biomarker was close to normal.  
The patients with early surgery in complete 
spinal cord injury and with a favorable 
outcome had a specific pattern of daily values 
of pNF-H: a sudden increase up to a maximum 
value then a gradual decrease to normal; the 
peak was different in each case, from 10 times 
up to 170 times higher than normal. (Figure 1) 
The same type of the pattern for the values 
of pNF-H appears in the incomplete spinal 
cord injury with favorable outcome, but with 
smaller values of pNF-H.  
There are two patterns in cases with 
unfavorable outcome or neurological 
stationary after the same early surgery and 
treatment: 
- the second unfavorable pattern had a 
progressive increase up to a peak and then was 
followed by a progressive decrease to normal 
values, the peak was a hundred times higher 
than normal values (Figure2),  
- an increase to a plateau of pNF-H values, 
with increased values five or ten times higher 
than normal (Figure 3). 
In patients with favorable development the 
progressive decrease of pNF-H values after the 
initial sudden increase, without extension of 
increased values in plateau or without a second 
peak, signifies a reduction or even a stop of the 
secondary lesion with evident effect on the 
favorable outcome in the spinal cord injury 
(Figure 4). 
 
 
Figure 1 - Pattern of daily value of pNF-H in patients 
with favorable outcome 
 
 
Figure 2 - Pattern with progressive increase of pNF-H 
 
 
Figure 3 - Pattern with increase up to a plateau of pNF-H 
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Figure 4 - The three specific and predictive pattern of daily values of pNF-H in traumatic SCI 
 
Kato et al. (2015) investigated the 
phosphorylated form of the high molecular 
weight neurofilament subunit (pNF-H) levels 
in the serum in patients with cervical 
compressive myelopathy and they found an 
elevated serum level of pNF-H only in acute 
worsening of myelopathy and this study 
confirms that pNF-H is a lesional biomarker. 
Kuhle et al. (2015) presented their results on a 
study of serum neurofilament light chain 
(pNF-L) in human spinal cord injury. They 
concluded that serum neurofilament light 
subunit (pNF-L) concentration in SCI patients 
has a close correlation with acute severity and 
neurological outcome and it is of predictive 
value in SCI patients. 
The presentation of these studies on 
biomarkers in SCI highlights that the most 
important ones and those with significant 
results relate to lesional biomarkers, and first 
are the phosphorylated neurofilament 
subunits, light or heavy (pNF-L or pNF-H), 
resulting from the axonal neurofilament 
destruction. The research showed that the 
phosphorylated neurofilament subunit, light 
or heavy (pNF-L or pNF-H) in spinal cord 
injury is a specific lesional biomarker for 
spinal cord injury and it can distinguish the 
severity of SCI. 
The heavy phosphorylated neurofilament 
subunit (pNF-H) is a predictive lesional 
biomarker because its values pattern can show 
the reducing or stopping of the secondary 
lesions and the favorable outcome. The 
complete SCI patients with a favorable 
development had a specific pattern of daily 
values of pNF-H: a sudden increase up to a 
maximum value then a progressive decrease to 
normal. The patients with unfavorable 
outcome or neurological stabilization had two 
patterns: an increase to a plateau of pNF-H 
values or a progressive increase up to a peak 
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followed by a progressive decrease to quasi-
normal values. 
Conclusion  
These studies on biomarkers in spinal cord 
injuries highlights that the most important 
lesional biomarkers are the phosphorylated 
neurofilament subunits, light or heavy (pNF-L 
or pNF-H). The phosphorylated 
neurofilament subunits, (pNF-L or pNF-H) 
are specific lesional biomarkers for spinal cord 
injury and they can distinguish the severity of 
SCI.  
The heavy phosphorylated neurofilament 
subunit (pNF-H) is a predictive lesional 
biomarker; its values pattern show the 
reducing or stopping of the secondary lesions 
and the favorable outcome.  
There is a specific pattern of daily values of 
pNF-H in complete SCI patients with a 
favorable outcome: a sudden increase up to a 
maximum value then a progressive decrease to 
normal. Also there are two patterns in the 
patients with unfavorable outcome: an 
increase to a plateau of pNF-H values or a 
progressive increase up to a peak followed by a 
progressive decrease to quasi-normal values. 
These specific patterns could be used to aid 
clinicians with making a diagnosis and 
establishing a prognosis, and evaluating 
therapeutic interventions. These studies 
should continue on larger groups of patients to 
prove the clinical usefulness. 
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